HemoCath Ltd. is an early-stage Canadian/US/Irish company that has developed and is now commercializing outside the United States the HemoCath Pulmonary Artery (PA) Catheter, indicated for the assessment of a patient’s hemodynamic condition through direct simultaneous CVP and PAP monitoring.
HemoCath-guided healthcare for patients with heart failure has the potential to improve clinical outcomes and reduce hospital length of stay. HemoCath PA Catheter is less invasive due to its 4F catheter size and easier-to-use by design.
HemoCath-guided healthcare for patients with heart failure has the potential to improve clinical outcomes and reduce hospital length of stay. HemoCath PA Catheter is less invasive due to its 4F catheter size and easier-to-use by design.